Skip to main content
. Author manuscript; available in PMC: 2018 May 16.
Published in final edited form as: Cell Rep. 2017 May 16;19(7):1304–1312. doi: 10.1016/j.celrep.2017.04.065

Figure 4.

Figure 4

mTR deficiency does not majorly impact iBIP phenotypes.

(A) Melanoma latency in BRAF-mutant mice with or without mTR deficiency.

(B) Progression-free survival on the BRAF inhibitor PLX4720 in iBIP mice with or without mTR deficiency.

(C) Number of non-synonymous mutations in BRAFi-resistant iBIP mice with or without mTR deficiency.

(D) Allelic fractions in the 10 mTR-null, BRAFi-resistant tumors.

(E) Summarization of results. Blue text indicates genomic status (mutation + SCNAs).